Sage Therapeutics Inc [NASDAQ: SAGE] stock went on an upward path that rose over 35.14% on Monday, amounting to a one-week price increase of more than 22.15%.
Over the last 12 months, SAGE stock dropped by -70.47%. The one-year Sage Therapeutics Inc stock forecast points to a potential upside of 9.09. The average equity rating for SAGE stock is currently 2.78, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $458.80 million, with 61.17 million shares outstanding and 53.88 million shares in the current float. Compared to the average trading volume of 1.06M shares, SAGE stock reached a trading volume of 12062759 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Sage Therapeutics Inc [SAGE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SAGE shares is $8.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SAGE stock is a recommendation set at 2.78. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Sage Therapeutics Inc shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on November 21, 2024. While these analysts kept the previous recommendation, Raymond James raised their target price to Mkt Perform. The new note on the price target was released on October 10, 2024, representing the official price target for Sage Therapeutics Inc stock. Previously, the target price had yet another drop from $10 to $4, while RBC Capital Mkts kept a Sector Perform rating on SAGE stock. On July 30, 2024, analysts decreased their price target for SAGE shares from 16 to 10.
The Average True Range (ATR) for Sage Therapeutics Inc is set at 0.55, with the Price to Sales ratio for SAGE stock in the period of the last 12 months amounting to 4.31. The Price to Book ratio for the last quarter was 0.83, with the Price to Cash per share for the same quarter was set at 9.33.
SAGE Stock Performance Analysis:
Sage Therapeutics Inc [SAGE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 22.15. With this latest performance, SAGE shares gained by 34.65% in over the last four-week period, additionally sinking by -36.22% over the last 6 months – not to mention a drop of -70.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SAGE stock in for the last two-week period is set at 70.28, with the RSI for the last a single of trading hit 75.63, and the three-weeks RSI is set at 65.17 for Sage Therapeutics Inc [SAGE]. The present Moving Average for the last 50 days of trading for this stock 5.65, while it was recorded at 6.22 for the last single week of trading, and 9.33 for the last 200 days.
Insight into Sage Therapeutics Inc Fundamentals:
Sage Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.02 and a Current Ratio set at 10.02.
Sage Therapeutics Inc [SAGE] Institutonal Ownership Details
There are presently around $86.40%, or 98.09%% of SAGE stock, in the hands of institutional investors. The top three institutional holders of SAGE stocks are: VANGUARD GROUP INC with ownership of 6.42 million shares, which is approximately 10.6696%. FMR LLC, holding 5.82 million shares of the stock with an approximate value of $$63.24 million in SAGE stocks shares; and FMR LLC, currently with $$59.52 million in SAGE stock with ownership which is approximately 9.1136%.
